Tony Huge

Can Enclomiphene Get Testosterone Over 1,000? Tony Huge’s Video Guide

Table of Contents

More than 1,100 men have been through enclomiphene trials, and exactly one of those trials ever counted how many blood samples crossed 1,000 ng/dL. What it printed is not what anyone online is quoting. Tony Huge goes through every published record of enclomiphene testosterone levels, the registry postings, and the sponsor’s own tables, and ends up with a different question: why did a company that drew blood every hour for 24 hours stop counting at 500?

Video: Can Enclomiphene Get Testosterone Over 1,000? What the Clinical Trials Actually Show. Published August 11, 2026. Watch on YouTube.

What the video covers

The trials were built to prove something else

Tony’s first move is to explain who the men in these trials were. Every one of them had to prove low testosterone with two separate early morning draws at or below 300 ng/dL, so starting levels sat between 200 and 295. A man going from 200 to 600 is a massive result in that context, and still a long way from 1,000.

Then there is the definition of success. The sponsor chose a band in advance that ran all the way up to 1,040, so a man finishing at 305 scored a success in the same column as a man finishing at 900. Four out of five men finished inside it, though those numbers are registry postings never peer reviewed. Tony’s reading is that a reference range describes where men land, not a dial you set, and that defining success this way is standard endocrinology practice, a comfortable way to win, and a much lower bar than the one a guy on Google has in his head.

Two samples out of 272

Only one trial could answer the 1,000 question, because only one drew blood hourly. Tony cites the 2013 study: randomized, single blind, three enclomiphene doses plus a gel arm, 48 men in and 44 finished, blood drawn every hour for 24 hours on two occasions. On the highest dose, two of 272 samples came back above 1,000. On the two lower doses, zero. The gel produced 17 of 305. The paper prints those as 1% and 6%, with no p value.

“Read that as two men out of 272 and you have just made the error the entire internet makes with this number.”

Tony Huge, 03:25

Those 272 samples came from 12 men. Two samples over 1,000 could be one man in one hour on one day, or two men on two days, and the paper never says. The same goes for the 17 gel samples, which came from 13 men. Tony’s summary is that this is unmeasured, not disproven. Nobody has shown enclomiphene does not cross 1,000. Nobody has shown that it does.

At six weeks the trial reported 604 on the highest dose, up from 253, measured at the trough, against 500 on gel, with a p value of 0.23 across 12 men versus 13. It could not tell the two drugs apart and was never built to. Tony also flags an inversion: the middle dose sat below the bottom dose, and while that group had only seven men, the same inversion shows up in a 26-week trial with 499 men, where noise cannot explain it.

Where the counting stopped

Putting the whole field on one scale, Tony finds three doses across five trials, six weeks out of 48, and every average between 404 and 604. The 400 and 500 cutoffs were counted: on the highest dose, 12 of 12 men got above 400 and 8 of 12 above 500, which with 12 men spans 35% to 90%. The ladder of cutoffs anyone ever counted men against runs 300, 400, 450, 500, and stops. The same paper used 1,000 as an outlier boundary for samples, so it was already in the file the day the 400 and 500 tables were built.

The two large trials reported daily averages in the 300s at week 16 and nobody above 1,040, but that was an average rather than a peak, nobody reported peaks, and 1,040 was the top of the sponsor’s assay range. A full-year fixed-dose randomized trial exists only as a registry posting; Tony’s arithmetic from the posted baseline and change puts week 48 around 417 and 455. Two independent reviews with no industry funding land in the same place, roughly 200 to 270 points added from a 250 baseline, though the larger review carries 89% heterogeneity and counts clomiphene alongside enclomiphene. The highest enclomiphene figure anywhere, 805, comes from a 15-man retrospective with no control group, five active ingredients in one product, and a baseline above the entry cutoff for every randomized trial.

Why more pill does not mean more testosterone

The mechanism explains the whole pattern. Injected testosterone is testosterone going in, so more in means more in your blood, close to linear. Tony cites a 2001 government-funded study of 61 healthy men over 20 weeks, own production switched off with a GnRH agonist, weekly injected testosterone under laboratory conditions, and the staircase walks straight through 1,000 somewhere between 125 and 300 mg a week.

Enclomiphene adds nothing. It blocks an estrogen receptor in the brain, the pituitary stops getting the signal that says there is enough, and more LH goes to the testicles. The ceiling is not set by the pill, it is set by what your testicles can make once the brakes come off. Tony cites the study that tested this directly: 52 men, 14 days, five groups, enclomiphene at 12.5, 25, and 50 mg against gel and placebo. Testosterone rose with every step, statistically significant, so the drug is genuinely dose responsive. But every enclomiphene group, including 50 mg, landed between 400 and 700 ng/dL, while the gel went straight past the natural limit. He adds one caveat from his own side: research subjects he has supervised at 50 mg did produce higher levels than that, though the trial was 14 days, 52 men, and nothing was stacked with it.

The honest argument for enclomiphene, in Tony’s words, is not altitude but stability. Across a full day it varied 21% and not one sample fell below 300. The gel varied 79%, dropped 50 samples below 300, and put 17 above 1,000, running both directions at once.

Cheat Sheet Pivot

What the trials Tony cites administered and what he reported, not instructions for anyone.

  • The trials used 12.5, 25, and 50 mg enclomiphene daily; the 50 mg arm was only ever run for 14 days, and the long-term arms topped out at 25 mg.
  • Every published enclomiphene average sits between 404 and 604 ng/dL, and no cutoff above 500 was ever counted against men.
  • The only thing on Tony’s chart that crosses 1,000 in a published average is injected testosterone at roughly double a replacement dose, which shuts off your own production.
  • Tony says the protocols he uses do get research subjects above 1,000 and do include enclomiphene, stacked with other things in what he calls a multi-pathway approach. He declines to describe them on YouTube.
  • The lower result on 25 mg than 12.5 mg across trials is, in his reading, a selection artifact: the only men moved to the higher dose were the ones who failed on the lower one.

Enclomiphene’s entry alongside the rest of the hormone catalog is in the Miracle Molecules Cheat Sheet. For why the enclomiphene half of clomiphene behaves so differently, read Enclomiphene vs Clomid: Same Molecule, Opposite Effects, and for Tony’s own experience running it, see Enclomiphene: The TRT Alternative That Keeps You Fertile.

Where the evidence stops

Tony names the incentive rather than a conspiracy. One company, Repros Therapeutics, sponsored, ran, analyzed, and co-authored every trial on the chart. The 2013 paper declares no conflict of interest while six of its nine authors list the company as employer on the same page. A sponsor decides which tables get built, and every table here was built to get a molecule approved: moving men from 200 into the normal range does that, while finding out how high a man can go does not. The company walked away from the research in 2021, and enclomiphene has no FDA approval for this use.

So the answer is two of 272 blood samples in 12 men with no statistical test, and a literature that stopped counting at 500 by choice rather than by limitation. Tony’s larger claim is that the clinical record is a map of what somebody had a commercial reason to measure, not a map of what is possible. He is equally clear about the other side: bloodwork on a forum is anecdote, and anecdote tells you where to look, not what is true.

Keep going

If the goal is keeping your own axis running alongside testosterone, HCG With TRT: Keep Your Testicles, Fertility and Estrogen covers the other tool Tony uses. New companion articles reach the tonyhuge.is email list first, and the full testosterone archive lives on tonyhuge.is.

Popular Category